HK1208348A1 - Cyclopropyl amide derivatives targeting the histamine h3 receptor - Google Patents

Cyclopropyl amide derivatives targeting the histamine h3 receptor Download PDF

Info

Publication number
HK1208348A1
HK1208348A1 HK15108903.2A HK15108903A HK1208348A1 HK 1208348 A1 HK1208348 A1 HK 1208348A1 HK 15108903 A HK15108903 A HK 15108903A HK 1208348 A1 HK1208348 A1 HK 1208348A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
compound
cyclopropyl
carbonyl
trans
Prior art date
Application number
HK15108903.2A
Other languages
English (en)
Chinese (zh)
Inventor
．格里芬
A.格里芬
Original Assignee
阿斯利康(瑞典)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1208348(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 阿斯利康(瑞典)有限公司 filed Critical 阿斯利康(瑞典)有限公司
Publication of HK1208348A1 publication Critical patent/HK1208348A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15108903.2A 2009-02-20 2015-09-11 Cyclopropyl amide derivatives targeting the histamine h3 receptor HK1208348A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15406709P 2009-02-20 2009-02-20
US61/154,067 2009-02-20

Publications (1)

Publication Number Publication Date
HK1208348A1 true HK1208348A1 (en) 2016-03-04

Family

ID=42631518

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108903.2A HK1208348A1 (en) 2009-02-20 2015-09-11 Cyclopropyl amide derivatives targeting the histamine h3 receptor

Country Status (39)

Country Link
US (3) US8993577B2 (enExample)
EP (1) EP2398780B1 (enExample)
JP (2) JP5666480B2 (enExample)
KR (1) KR20110126628A (enExample)
CN (2) CN104398516A (enExample)
AR (1) AR075531A1 (enExample)
AU (1) AU2010216454B2 (enExample)
BR (1) BRPI1007817A2 (enExample)
CA (1) CA2752796A1 (enExample)
CO (1) CO6400219A2 (enExample)
CR (1) CR20110447A (enExample)
CU (2) CU20110161A7 (enExample)
DK (1) DK2398780T3 (enExample)
DO (1) DOP2011000270A (enExample)
EA (2) EA020093B1 (enExample)
EC (1) ECSP11011280A (enExample)
ES (1) ES2416464T3 (enExample)
HK (1) HK1208348A1 (enExample)
HN (1) HN2011002261A (enExample)
HR (1) HRP20130579T1 (enExample)
IL (1) IL214277A (enExample)
ME (1) ME01619B (enExample)
MX (1) MX2011008280A (enExample)
NI (1) NI201100160A (enExample)
NZ (1) NZ595248A (enExample)
PE (2) PE20151281A1 (enExample)
PL (1) PL2398780T3 (enExample)
PT (1) PT2398780E (enExample)
RS (1) RS52851B (enExample)
SA (1) SA110310136B1 (enExample)
SG (1) SG173449A1 (enExample)
SI (1) SI2398780T1 (enExample)
SM (1) SMT201300077B (enExample)
SV (1) SV2011004008A (enExample)
TW (1) TW201039825A (enExample)
UA (1) UA108841C2 (enExample)
UY (1) UY32460A (enExample)
WO (1) WO2010096011A1 (enExample)
ZA (1) ZA201106821B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0712823A2 (pt) * 2006-06-23 2012-07-24 Abbott Lab derivados de ciclopropil amina como moduladores de receptor de histamina h3
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
TW201446748A (zh) 2007-08-22 2014-12-16 Astrazeneca Ab 環丙基醯胺衍生物
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
SG183231A1 (en) * 2010-02-18 2012-09-27 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
NZ602110A (en) * 2010-02-18 2014-09-26 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
GEP20207149B (en) 2016-03-22 2020-09-10 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
US20230365589A1 (en) 2020-09-18 2023-11-16 Sumitomo Pharma Co., Ltd. Novel amine derivatives
CN114790186A (zh) * 2021-01-25 2022-07-26 武汉人福创新药物研发中心有限公司 作为ep4拮抗剂的稠环化合物及其制备方法和用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (enExample) 1963-04-04 1900-01-01
NL128365C (enExample) 1963-11-05
US3449427A (en) 1965-06-03 1969-06-10 Smithkline Corp Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes
US3697506A (en) 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3686335A (en) 1970-12-21 1972-08-22 Smith Kline French Lab 5-vinyl-5h-di benzo(a,d)cycloheptenes
US4432987A (en) 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4547505A (en) 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
CS244821B2 (en) 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
DE3418167A1 (de) 1984-05-16 1985-11-21 Bayer Ag, 5090 Leverkusen Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden
DE3600288A1 (de) 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
DE3618004A1 (de) 1986-05-28 1987-12-03 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
EP0435320B1 (en) 1989-12-29 1994-10-05 Banyu Pharmaceutical Co., Ltd. 2(2-Cyclopropylpyrrolidin-4-ylthio)-carbapenem derivatives
JPH06505502A (ja) 1991-08-22 1994-06-23 モンサント・カンパニー 毒性緩和除草剤ピラゾリルスルホニル尿素
DE4131139A1 (de) 1991-09-19 1993-03-25 Bayer Ag Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
DE69427469T2 (de) 1993-03-12 2001-10-31 Pharmacia & Upjohn Co., Kalamazoo Kristallines ceftiofur (freie säure)
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
EP0968200A1 (en) 1997-02-24 2000-01-05 ZymoGenetics, Inc. Calcitonin mimetics
US6160134A (en) 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
EA200000768A1 (ru) 1998-01-27 2001-06-25 Эвентис Фармасьютикалз Продактс Инк. ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
EP1090919A4 (en) 1998-06-26 2002-05-22 Chugai Pharmaceutical Co Ltd L-ALPHA-AMINOADIPIC ACID DERIVATIVE IN FINE POWDER, ORAL SOLID PREPARATIONS CONTAINING SAID DERIVATIVE AND BULK POWDER PROCESSING PROCESS
CN1167694C (zh) 1999-01-08 2004-09-22 纽罗根公司 1-苯基-4-(1-[2-芳基]环丙基)甲基哌嗪:多巴胺受体配体
US6284761B1 (en) 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
AU5426500A (en) 1999-06-16 2001-01-02 Takeda Chemical Industries Ltd. Benzazepine derivatives, process for the preparation of the same and uses thereof
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
AU2930501A (en) 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CN1242989C (zh) 2000-06-29 2006-02-22 艾伯特公司 芳基苯基环丙基硫醚衍生物及其作为抑制细胞粘附的抗炎和免疫抑制剂的用途
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
KR20030024799A (ko) 2000-07-20 2003-03-26 뉴로젠 코포레이션 캡사이신 수용체 리간드
KR20030062447A (ko) 2000-12-25 2003-07-25 아지노모토 가부시키가이샤 광학 활성 할로하이드린 화합물의 제조방법
PT1379520E (pt) 2001-02-23 2006-08-31 Merck & Co Inc Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
CA2456754A1 (en) 2001-08-08 2003-02-20 Yuji Iizawa Benzazepine derivative, process for producing the same, and use
EP1442038A4 (en) 2001-09-26 2005-01-05 Merck & Co Inc CRYSTALLINE FORMS OF CARBAPENEM ANTIBIOTICS AND MANUFACTURING METHOD
WO2003037271A2 (en) 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CN1642947A (zh) 2002-03-22 2005-07-20 株式会社Lg生命科学 ( 2 S )－N－5－[氨基(亚氨基)甲基]－2－噻吩基甲基－1－( 2 R ) －2－[(羧甲基) 氨基]－3 ,3－二苯基丙酰－2－吡咯烷甲酰胺·nH2O的新晶形
AU2003236686A1 (en) 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo(4,5,1-j) quinolin-6-ones as parp inhibitors
US20040209858A1 (en) 2002-10-22 2004-10-21 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
US20040077618A1 (en) 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
JPWO2004046110A1 (ja) 2002-11-15 2006-03-16 アステラス製薬株式会社 メラニン凝集ホルモン受容体拮抗剤
DE60318891T2 (de) 2002-12-13 2009-01-22 Smithkline Beecham Corp. Cyclopropylverbindungen als ccr5 antagonisten
SI1615909T1 (sl) 2003-04-23 2008-12-31 Glaxo Group Ltd Derivati piperazina in njihova uporaba za zdravljenje nevroloĺ kih in psihiatriäśnih bolezni
WO2004099156A1 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
CN1901971A (zh) 2003-12-15 2007-01-24 日本烟草产业株式会社 环丙烷化合物及其药物应用
AU2004321997A1 (en) 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
ATE499356T1 (de) 2004-09-29 2011-03-15 Mitsubishi Tanabe Pharma Corp 6-(pyridinyl)-4-pyrimidonderivate als inhibitoren der tau-proteinkinase-1
HRP20080227T3 (hr) 2004-10-15 2008-06-30 Glaxo Group Limited Pirolidinski derivati kao ligandi histaminskih receptora
CN101128435A (zh) 2004-12-27 2008-02-20 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体激动剂用于治疗神经病学及精神病学病症的吡唑酮化合物
WO2006079916A1 (en) 2005-01-26 2006-08-03 Pharmacia & Upjohn Company Llc Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
WO2006087169A1 (en) 2005-02-15 2006-08-24 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine
EP1849773B1 (en) 2005-02-17 2013-10-16 Astellas Pharma Inc. Piperazine derivatives for the treatment of urinary incontinence and pain
US20080176857A1 (en) 2005-03-25 2008-07-24 Michael Dalton Ennis 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors
WO2006103544A2 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2602538A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
JP2008534571A (ja) 2005-03-28 2008-08-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 血小板凝集阻害物質としての４−ピペラジニルチエノ［２，３−ｄ］ピリミジン化合物
JP2009501235A (ja) 2005-07-15 2009-01-15 シェーリング コーポレイション 癌処置において有用なキナゾリン誘導体
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
PT1948607E (pt) * 2005-09-16 2010-06-02 Janssen Pharmaceutica Nv Ciclopropilaminas como moduladores do receptor h3 de histamina
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
NZ592864A (en) 2005-10-31 2012-09-28 Janssen Pharmaceutica Nv Processes for the preparation of cyclopropyl-amide derivatives
EP2308872A1 (en) 2005-12-21 2011-04-13 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2007076140A2 (en) 2005-12-23 2007-07-05 University Of Cincinnati Treatment methods employing histamine h3 receptor antagonists, including betahistine
RU2008132966A (ru) 2006-01-13 2010-02-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные циклогексилпиперазинилметанона и их применение в качестве модуляторов гистамин н3 рецептора
CN101384581B (zh) 2006-02-17 2013-09-18 弗·哈夫曼-拉罗切有限公司 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物
EP2004568A4 (en) 2006-03-01 2010-12-01 Cementech Pty Ltd MATRIX FOR MASONRY ELEMENTS AND METHOD FOR MANUFACTURING THE SAME
JP2009132621A (ja) 2006-03-13 2009-06-18 Ajinomoto Co Inc シクロプロピルアミド化合物の製造方法
US7524848B2 (en) 2006-03-23 2009-04-28 Amgen Inc. Diaza heterocyclic amide compounds and their uses
WO2007138928A1 (ja) 2006-05-26 2007-12-06 Kaneka Corporation 光学活性３－アミノ－２－ヒドロキシプロピオン酸シクロプロピルアミド誘導体およびその塩の製造方法
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
BRPI0712823A2 (pt) * 2006-06-23 2012-07-24 Abbott Lab derivados de ciclopropil amina como moduladores de receptor de histamina h3
CA2657702A1 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek E N Patieentenzorg Quinazolines and related heterocyclic comp0unds, and their therapeutic use
WO2008024284A2 (en) 2006-08-21 2008-02-28 Merck & Co., Inc. Sulfonylated piperazines as cannabinoid-1 receptor modulators
TW200828371A (en) 2006-09-21 2008-07-01 Matsushita Electric Industrial Co Ltd Chip-type filter
DE102006056526A1 (de) 2006-11-30 2008-06-05 Archimica Gmbh Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008147864A2 (en) 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
JP2010528007A (ja) 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピロリジンオレキシン受容体アンタゴニスト
ES2350511T3 (es) * 2007-06-11 2011-01-24 F. Hoffmann-La Roche Ag Derivados ciclohexilo.
TW201446748A (zh) * 2007-08-22 2014-12-16 Astrazeneca Ab 環丙基醯胺衍生物
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
AR070107A1 (es) 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
DE102008049371A1 (de) 2008-03-06 2009-09-10 Mühlbauer Ag Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür
US8691804B2 (en) 2008-05-08 2014-04-08 Evotec Ag Azetidines and cyclobutanes as histamine H3 receptor antagonists
EP2313360B1 (en) 2008-07-28 2012-09-05 Syddansk Universitet Compounds for the treatment of metabolic diseases
CN101462980B (zh) 2009-01-05 2013-01-09 扬州天辰精细化工有限公司 2，6—二氟苯甲酰胺的工业化生产方法
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
SG183231A1 (en) 2010-02-18 2012-09-27 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
NZ602110A (en) 2010-02-18 2014-09-26 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith

Also Published As

Publication number Publication date
EA020093B1 (ru) 2014-08-29
AU2010216454A1 (en) 2011-08-25
EP2398780B1 (en) 2013-04-17
CN104398516A (zh) 2015-03-11
CN102405213A (zh) 2012-04-04
RS52851B (sr) 2013-12-31
WO2010096011A1 (en) 2010-08-26
SV2011004008A (es) 2012-01-06
HK1164863A1 (en) 2012-09-28
SA110310136B1 (ar) 2014-01-14
NI201100160A (es) 2012-03-15
SMT201300077B (it) 2013-09-06
HRP20130579T1 (en) 2013-07-31
KR20110126628A (ko) 2011-11-23
CR20110447A (es) 2011-09-19
JP2015071634A (ja) 2015-04-16
EP2398780A1 (en) 2011-12-28
MX2011008280A (es) 2011-08-24
BRPI1007817A2 (pt) 2017-05-30
UY32460A (es) 2010-09-30
IL214277A (en) 2015-08-31
DK2398780T3 (da) 2013-07-01
ECSP11011280A (es) 2011-09-30
US20150164888A1 (en) 2015-06-18
ES2416464T3 (es) 2013-08-01
US8993577B2 (en) 2015-03-31
SG173449A1 (en) 2011-09-29
CU20110161A7 (es) 2012-02-15
AU2010216454B2 (en) 2013-05-02
ME01619B (me) 2014-09-20
AR075531A1 (es) 2011-04-06
CU20140013A7 (es) 2014-04-24
TW201039825A (en) 2010-11-16
CO6400219A2 (es) 2012-03-15
JP5666480B2 (ja) 2015-02-12
CA2752796A1 (en) 2010-08-26
SI2398780T1 (sl) 2013-08-30
UA108841C2 (ru) 2015-06-25
EP2398780A4 (en) 2012-09-19
US20100216812A1 (en) 2010-08-26
ZA201106821B (en) 2012-06-26
HN2011002261A (es) 2014-07-31
NZ595248A (en) 2014-01-31
US20150164889A1 (en) 2015-06-18
PE20120063A1 (es) 2012-03-04
CN102405213B (zh) 2014-11-19
PT2398780E (pt) 2013-06-25
JP2012518634A (ja) 2012-08-16
EA201190140A1 (ru) 2012-03-30
IL214277A0 (en) 2011-09-27
PL2398780T3 (pl) 2013-08-30
PE20151281A1 (es) 2015-10-04
DOP2011000270A (es) 2012-08-31
EA201490268A1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
CN102405213B (zh) 靶向于组胺h3受体的环丙基酰胺衍生物
KR101588466B1 (ko) 시클로프로필 아미드 유도체
KR20130002316A (ko) 시클로프로필 벤즈아미드 유도체의 신규 결정질 형태
JP5746718B2 (ja) シクロプロピルアミド誘導体からなる固体形態
US20100130477A1 (en) Spirocyclobutyl Piperidine Derivatives
HK1164863B (en) Cyclopropyl amide derivatives targeting the histamine h3 receptor
AU2013209365A1 (en) Cyclopropyl amide derivatives targeting the histamine h3 receptor
HK1144687B (en) Cycloptopyl amide derivatives